Share this to:

Support & Insight for the Autumn of Life

Future & Current Alzheimer’s Drugs

MEDICATION-MINUTE VIDEO:

A plain-English look at dementia medications. Learn about current and future drugs. See what to expect in the years ahead from Biogen, Eli Lilly and other labs.



SOURCE:

  • CNBC.com
Subscribe
Notify of
guest

1 Comment
Inline Feedbacks
View all comments
Unknown
Unknown
6 years ago

We can find articles that proved that Solanezumab is a failed drug, searching in Google with the words "Solanezumab failure" .For example the scientific article published in the New England Journal of Medicine, 2014"title:
"Phase 3 Trials of Solanezumab for Mild l-to-Moderat Alzheimer's disease. "Authors: Doody and colleagues,from the Alzheimer's Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston,U.S.A.,where we can read: " "Conclusion:Solanezumab, a humanized monoclonal antibody,that binds amyloid, FAILED to improves cognition or functional ability"

B. Berger

B. Berger

Visit Our Pages On:

Welcome

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Related

160509-meds2.jpeg
Best Time to Stop Medicine for Dementia
140803-seminar.jpeg
Dementia Medications - Advanced Seminar
lewy-body-dementia%2Bby%2BT.%2BH.%2BJensen%2Bfrom%2BPixabay.jpeg
Neflamapimod May Be 1st Dementia with Lewy Bodies Drug

Books

Amazon Books
1
0
Would love your thoughts, please comment.x
()
x
News to Get at the Truth

Subscribe To Our Weekly Newsletter

Enjoy thought-provoking videos & articles
News to Get at the Truth

Subscribe To Our Weekly Newsletter